According to a Reuters report which cited two people close to the matter who remain unidentified, Pfizer may be selling its consumer healthcare business next month in an auction.
The insiders revealed that if a sale happens, it could be valued at over $15 billion.
The company’s consumer healthcare business covers all kinds of medications from headache to colds and even digestive health. It had $3.4 billion in sales last year.
In the past GlaxoSmithKline as well as Reckitt Benckiser have shown interest in the unit.
Centerview Partners, Guggenheim Securities and Morgan Stanley are leading the prospective sale, but earlier in the month, Pfizer had said it was considering strategic options for the business.
We will have to wait and see what happens.
Disclaimer: We have no position in Pfizer Inc. (NYSE: PFE) and have not been compensated for this article.